Alchemab Therapeutics LtdFinancingAlchemab Therapeutics reports US$32m Series A extensionBritish antibody specialist Alchemab Therapeutics Ltd has secured a US$32m Series A extension after it completing preclinical development of ATLX-1282 and starting a Phase I clinical trial. more ➔
FRAXA Ewsearch OrganisationPartnership Servier acquires Kaerus Bioscience’s FXS candidate for US$450mIn a US$450m deal with UK-based Kaerus Bioscience Ltd, Servier SA has acquired the development and commercialisation rights to KER-0193, a Phase II-ready drug candidate for the treatment of rare Fragile … more ➔
adobe stock photos - deemerwhafinancingNRG Therapeutics Ltd bags £50m in Series B financingBritish mitochondrial dysfunction specialist NRG Therapeutics Ltd. (“NRG”) has closed an oversubscribed £50m Series B financing. Funds will be used to to achieve clinical proof of concept for NRG5051 … more ➔
Marcus Krauss - stock.adobe.com ADCsBioNTech‘s breast cancer ADC outperforms Roche’s KadcylaData on the primary endpoint of BioNTech’s/Duality Biologics’ pivotal Phase III study of its HER2 antibody-drug conjugate BNT323/DB-1303 are not yet public, However, BioNTech says that progression-free … more ➔
adobe stock photo - Blackmint StudioFood BiotechnologyAlt protein: EASAC sees immediate need for actionExperts from the six science academies united in EASAC have called for the immediate establishment of a transparent framework across the EU for the production of biotechnologically manufactured meat … more ➔
adobe stock photos - nobeastsofierce AntiinflammationMicrobiome play MRM Health NV raises €55m in Series BBelgian VIB spin-out MRM Health NV is using fresh funds raised in a €55m follow-on financing round to make its microbiome preparation MH002 licensable in an ongoing Phase IIb study for the indication … more ➔
Marvin 101 - wikipedia.orgLicence dealNovartis invests US$200min lacklustre Parkinson’s targetSwiss pharma major Novartis AG is investing money in the inhibition of the Parkinson’s target alpha-synuclein, which has already failed several times in clinical trials. The Swiss company is licensing … more ➔
By Coolcaesar - wikipedia.orgCardiology Cytokinetics’ Aficamten with breakthrough Phase III resultsCalifornia-based Cytokinetics Inc (CYTK) recorded a big jump in Nasdaq prices, at 40.45%, after presenting the results of its Phase III MAPLE-HCM study at the European Society of Cardiology Congress … more ➔
Polpharma Biologics SApartnershipPolpharma Biologics secures distribution of upcoming biosimilarsPolpharma Biologics SA and MS Pharma SA have signed licensing agreements for Polpharma’s vedolizumab (PB016), ocrelizumab (PB018) and guselkumab (PB019) biosimilars in the Middle East and North Africa … more ➔
adobe stock photos - Sundry Photography Licence agreementGenentech inks US$400m IBD deal with OMass TherapeuticsThe US Roche unit Genentech Inc has signed a US$400 million licence deal with British NativeMS specialist OMass Therapeutics Ltd. Under the exclusive collaboration and licence agreement, Genentech intends … more ➔
Alchemab Therapeutics Ltd
FRAXA Ewsearch Organisation
adobe stock photos - deemerwha
Marcus Krauss - stock.adobe.com 
adobe stock photo - Blackmint Studio
adobe stock photos - nobeastsofierce 
Marvin 101 - wikipedia.org
By Coolcaesar - wikipedia.org
Polpharma Biologics SA
adobe stock photos - Sundry Photography